Clinical trials
Mycoses trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
33 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 33 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assiut University | 7 |
| Bayside Health | 2 |
| Ruijin Hospital | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Azienda Ospedaliera di Padova | 1 |
| Catholic University of the Sacred Heart | 1 |
| Chang Gung Memorial Hospital | 1 |
| Chulalongkorn University | 1 |
| Fovea | 1 |
| Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mycoses | 33 |
| Bacterial Infections | 4 |
| Invasive Fungal Infections | 4 |
| Candidiasis | 2 |
| Infections | 2 |
| Neutropenia | 2 |
| AIDS-Related Opportunistic Infections | 1 |
| Acquired Immunodeficiency Syndrome | 1 |
| Acute Kidney Injury | 1 |
| Acute-On-Chronic Liver Failure | 1 |
Trials
Showing 76 to 33 of 33. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.